Does Medicare Cover Genvisc 850? (2026)

Quick Answer

Yes, Medicare Part B covers Genvisc 850 injections for knee osteoarthritis when medical necessity criteria are met. Genvisc 850 is often described as a biosimilar to Hyalgan and can be a more cost-effective viscosupplementation option. Most patients pay 20% coinsurance after meeting their Part B deductible.

Medicare Part B Coverage for Genvisc 850

Genvisc 850 is a sodium hyaluronate injection manufactured by OrthogenRx. It shares a similar composition and molecular weight to Hyalgan and is frequently used as an alternative at a lower cost. Medicare covers Genvisc 850 under Part B (the medical benefit) because it is administered in a physician’s office or outpatient setting.

Key coverage facts:

• Covered under Part B as a physician-administered injectable
• No prior authorization required under Original Medicare
• Subject to Local Coverage Determinations (LCDs) from your regional MAC
• Must meet medical necessity criteria documented in your medical records
• Cost-effective option that may lower out-of-pocket expenses compared to some other brands

Coverage Requirements

Medical Necessity Criteria

For Medicare to pay for Genvisc 850, your medical records must show:

• Diagnosis of knee osteoarthritis with ICD-10 code M17.x
• Failure of conservative treatment for at least 3 months, including physical therapy, NSAIDs, or activity modification
• Chart documentation confirming these approaches were not adequate
• X-ray evidence confirming osteoarthritis (most MACs require imaging within the past 12 months)

Billing Codes

Your provider bills Medicare using J-code J7320 for each Genvisc 850 injection. Note: J7320 is a shared HCPCS code also used for Hyalgan, since both products contain sodium hyaluronate with similar molecular weight. If your insurer questions the billing, your provider can specify “Genvisc 850” on the claim. Since Genvisc 850 is given as 3 to 5 injections, the code is billed for each injection in the series.

Frequency Limits

• Medicare typically covers one treatment course (3-5 weekly injections) per knee every 6 months
• Some MACs allow repeat treatment after 6 months if the initial series provided meaningful relief
• Bilateral knee treatment is generally covered when both knees have documented OA
• Your provider should document clinical response to support repeat courses

Your Out-of-Pocket Costs

Example Cost Calculation

If Medicare approves $150 per injection for a 5-injection course ($750 total):

• Medicare pays: $600 (80%)
• You pay: $150 (20%)
• If you have a Medigap plan: your supplement may cover some or all of that $150

Genvisc 850 typically has a lower Medicare-approved amount than some premium-priced HA brands, which can mean lower out-of-pocket costs for patients.

Medicare Advantage Plans

If you have a Medicare Advantage (Part C) plan:

• Coverage generally follows Original Medicare guidelines
• Prior authorization may be required — check with your plan before scheduling
• Copays vary by plan and may differ from the standard 20% coinsurance
• Network restrictions may apply — confirm your provider is in-network
• Some Advantage plans may prefer Genvisc 850 due to its lower cost — ask your plan about preferred brands

What If Medicare Denies Coverage?

If your Genvisc 850 claim is denied:

1. Request the denial reason in writing
2. Gather supporting documents including X-rays, treatment records, and your provider’s letter of medical necessity
3. File a redetermination (Level 1 appeal) within 120 days
4. Include clinical evidence showing viscosupplementation is medically necessary for your condition

Many initial denials are overturned on appeal with proper documentation.

Genvisc 850 Product Details

Genvisc 850 is frequently described as a biosimilar to Hyalgan, sharing a similar molecular weight and composition. While the term “biosimilar” is used informally in the viscosupplementation market (HA injectables are classified as medical devices, not biologics), Genvisc 850 provides a comparable treatment option at a potentially lower cost.

Frequently Asked Questions

How often will Medicare pay for Genvisc 850?

Medicare generally covers one treatment course per knee every 6 months. A course consists of 3 to 5 weekly injections. Your provider documents medical necessity and clinical benefit from prior treatment.

Do I need prior authorization for Genvisc 850 under Medicare?

No. Original Medicare does not require prior authorization for Genvisc 850. Medicare Advantage plans may have their own prior authorization rules. Check with your plan before scheduling.

Is Genvisc 850 covered under Medicare Advantage?

Yes. Medicare Advantage plans must cover everything Original Medicare covers. Some plans may actually prefer Genvisc 850 due to its lower cost profile. Contact your plan for specifics about cost-sharing and any preferred brand lists.

What is the difference between Genvisc 850 and Hyalgan?

Both are low molecular weight sodium hyaluronate products derived from avian sources, given as 3 to 5 weekly injections. Genvisc 850 is manufactured by OrthogenRx and Hyalgan by Fidia Pharma. They share similar composition and clinical properties. Genvisc 850 may have a lower acquisition cost. Both are covered by Medicare.

Is Genvisc 850 a true biosimilar?

Technically, HA viscosupplements are classified as medical devices by the FDA, not biological products. So the term “biosimilar” is used informally. Genvisc 850 has a very similar composition and molecular weight to Hyalgan, but it follows the medical device regulatory pathway, not the biosimilar approval pathway used for biologic drugs.

Related Resources

• Medicare Coverage for HA Injections
• Complete Medicare Coverage Guide
• Medicare Part B Coverage Details
• Hyaluronic Acid Injections Overview
• Compare HA Injection Brands